BACKGROUND AND PURPOSE: Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) in the treatment of haematological tumours and is currently approved for the treatment of many haematological malignancies. Navitoclax (ABT-263) is a potent inhibitor of Bcl-2, Bcl-x(L) and Bcl-w, which has demonstrated efficacy in haematological tumours alone and in combination with other agents. This paper describes the in vivo efficacy of combining either bendamustine or bendamustine plus rituximab (BR) with navitoclax in xenograft models of non-Hodgkin's lymphoma EXPERIMENTAL APPROACH: Activity was tested in xenograft models of diffuse large B-cell lymphoma (DoHH-2, SuDHL-4), mantle cell lymphoma (Granta 519) and Burkitt's lymphoma (RAMOS). Activity was also monitored in a systemic model of Granta 519. KEY RESULTS: Navitoclax potentiated bendamustine activity in all cell lines tested. Bendamustine activated p53 in Granta 519 tumours, concurrent with activation of caspase 3. Navitoclax also improved responses to bendamustine-rituximab (BR) in a subset of tumours. CONCLUSIONS AND IMPLICATIONS: Navitoclax in combination with bendamustine and BR is a viable combination strategy for use in the clinic and demonstrated superior efficacy compared with previously reported data for navitoclax plus CHOP and rituximab-CHOP.
BACKGROUND AND PURPOSE:Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy cyclophosphamide-doxorubicin-vincristine-prednisolone (CHOP) in the treatment of haematological tumours and is currently approved for the treatment of many haematological malignancies. Navitoclax (ABT-263) is a potent inhibitor of Bcl-2, Bcl-x(L) and Bcl-w, which has demonstrated efficacy in haematological tumours alone and in combination with other agents. This paper describes the in vivo efficacy of combining either bendamustine or bendamustine plus rituximab (BR) with navitoclax in xenograft models of non-Hodgkin's lymphoma EXPERIMENTAL APPROACH: Activity was tested in xenograft models of diffuse large B-cell lymphoma (DoHH-2, SuDHL-4), mantle cell lymphoma (Granta 519) and Burkitt's lymphoma (RAMOS). Activity was also monitored in a systemic model of Granta 519. KEY RESULTS:Navitoclax potentiated bendamustine activity in all cell lines tested. Bendamustine activated p53 in Granta 519 tumours, concurrent with activation of caspase 3. Navitoclax also improved responses to bendamustine-rituximab (BR) in a subset of tumours. CONCLUSIONS AND IMPLICATIONS: Navitoclax in combination with bendamustine and BR is a viable combination strategy for use in the clinic and demonstrated superior efficacy compared with previously reported data for navitoclax plus CHOP and rituximab-CHOP.
Authors: Kai U Chow; Wolf Daniel Sommerlad; Simone Boehrer; Bernd Schneider; Gernot Seipelt; Mathias Johannes Rummel; Dieter Hoelzer; Paris S Mitrou; Eckart Weidmann Journal: Haematologica Date: 2002-01 Impact factor: 9.941
Authors: Tilman Oltersdorf; Steven W Elmore; Alexander R Shoemaker; Robert C Armstrong; David J Augeri; Barbara A Belli; Milan Bruncko; Thomas L Deckwerth; Jurgen Dinges; Philip J Hajduk; Mary K Joseph; Shinichi Kitada; Stanley J Korsmeyer; Aaron R Kunzer; Anthony Letai; Chi Li; Michael J Mitten; David G Nettesheim; ShiChung Ng; Paul M Nimmer; Jacqueline M O'Connor; Anatol Oleksijew; Andrew M Petros; John C Reed; Wang Shen; Stephen K Tahir; Craig B Thompson; Kevin J Tomaselli; Baole Wang; Michael D Wendt; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg Journal: Nature Date: 2005-05-15 Impact factor: 49.962
Authors: Alex R Shoemaker; Anatol Oleksijew; Joy Bauch; Barbara A Belli; Tony Borre; Milan Bruncko; Thomas Deckwirth; David J Frost; Ken Jarvis; Mary K Joseph; Kennan Marsh; William McClellan; Hugh Nellans; ShiChung Ng; Paul Nimmer; Jacqueline M O'Connor; Tilman Oltersdorf; Weiguo Qing; Wang Shen; Jason Stavropoulos; Stephen K Tahir; Baole Wang; Robert Warner; Haichao Zhang; Stephen W Fesik; Saul H Rosenberg; Steven W Elmore Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701
Authors: R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder Journal: Proc Natl Acad Sci U S A Date: 1982-12 Impact factor: 11.205
Authors: M J Dyer; D M Lillington; C Bastard; H Tilly; D Lens; J M Heward; G Stranks; R Morilla; S Monrad; P Guglielmi; J C Kluin-Nelemans; A Hagemeijer; B D Young; D Catovsky Journal: Leukemia Date: 1996-07 Impact factor: 11.528
Authors: Tudor Moldoveanu; Ariele Viacava Follis; Richard W Kriwacki; Douglas R Green Journal: Trends Biochem Sci Date: 2014-02-03 Impact factor: 13.807
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Thomas J Kipps; Herbert Eradat; Sebastian Grosicki; John Catalano; Walter Cosolo; Iryna S Dyagil; Sreeni Yalamanchili; Akiko Chai; Srikumar Sahasranaman; Elizabeth Punnoose; Deborah Hurst; Halyna Pylypenko Journal: Leuk Lymphoma Date: 2015-05-12
Authors: Sven de Vos; John P Leonard; Jonathan W Friedberg; Jasmine Zain; Kieron Dunleavy; Rod Humerickhouse; John Hayslip; John Pesko; Wyndham H Wilson Journal: Leuk Lymphoma Date: 2020-11-25
Authors: Mona Darwish; Mary Bond; Edward Hellriegel; Philmore Robertson; James P Chovan Journal: Cancer Chemother Pharmacol Date: 2015-04-01 Impact factor: 3.333
Authors: Anthony W Tolcher; Wendi V Rodrigueza; Drew W Rasco; Amita Patnaik; Kyriakos P Papadopoulos; Alex Amaya; Timothy D Moore; Shari K Gaylor; Charles L Bisgaier; Mina P Sooch; Michael J Woolliscroft; Richard A Messmann Journal: Cancer Chemother Pharmacol Date: 2013-12-03 Impact factor: 3.333